Would you consider treatment with sacituzumab in triple negative metastatic breast cancer if there has been progression on irinotecan?

While I am not aware of any data on the efficacy of sacituzumab govitecan (SG) in such patients, not surprising since irinotecan is not commonly administered to such patients, I would not rule out a trial of this agent. We know that ado-trastuzumab emtansine can be effective in patients progressing ...

I do not use irinotecan in TNBC.

I have not yet encountered this in practice as irinotecan isn’t a chemotherapy that is used very frequently in breast cancer. Although the payload is SN-38, with sacituzumab being targeted to the cell via Trop-2, I think it would be reasonable to try with a close follow-up although we do not have sp...

Irinotecan is not a chemotherapy that most breast oncologists use so we don't have any data on this. I would likely still use Sacituzumab in this space.